NeuroOne (NMTC) Files 8-K; Press Release Dated Aug 14, 2025

NeuroOne Medical Technologies Corporation filed a Form 8-K reporting a material event by submitting a Press Release dated August 14, 2025.

Rhea-AI Filing Summary

NeuroOne Medical Technologies Corporation filed a Form 8-K reporting a material event by submitting a Press Release dated August 14, 2025. The filing identifies the company’s common stock ticker as NMTC on The Nasdaq Stock Market and lists an exhibit reference Exhibit 99.1 for the press release and a cover page interactive data file. The document is signed by David Rosa, Chief Executive Officer. The filing text provided here is brief and does not include the press release content, financial results, or details about the reported material event.

Positive

• Form 8-K filed and signed by the CEO on August 14, 2025
• Exhibit 99.1 press release and interactive data file were submitted, indicating formal disclosure procedures were followed

Negative

• Press release content not included in the provided text, so the material event’s substance is unavailable
• No financial or transaction details are present to assess investor impact

Insights

Corporate Communications Analyst

Filed an 8-K with an Exhibit 99.1 press release; substantive content is not included here.

The company submitted a Form 8-K identifying a press release as the material event and attached an interactive data file. The filing confirms the event was formally communicated under SEC procedures and was signed by the CEO on August 14, 2025.

Because the press release text is not present, the immediate near-term impact cannot be assessed from this filing alone; investors should consult the referenced Exhibit 99.1 press release for details and monitor any follow-up disclosures over the next few days.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did NeuroOne (NMTC) disclose in the Form 8-K dated August 14, 2025?

The filing states a Press Release (Exhibit 99.1) was submitted and the Form 8-K was signed by David Rosa, CEO. The substantive press release text is not included in the provided content.

Where is NMTC listed and what is the ticker symbol?

The company’s common stock is listed on The Nasdaq Stock Market under the ticker NMTC.

Does the provided 8-K include financial results or transaction details?

No. The supplied text does not contain earnings, financial tables, transaction descriptions, or other material details.

How can investors read the full press release referenced in the 8-K?

Investors should access the Form 8-K on the SEC’s EDGAR system or the company’s investor relations site to view Exhibit 99.1 for the full press release.

Who signed the 8-K filing for NMTC?

The filing is signed by David Rosa, Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 07:46 AM Learn about SEC filing dates

false 0001500198 0001500198 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 14, 2025

NeuroOne Medical Technologies Corporation

(Exact name of registrant as specified in its charter)

Delaware		001-40439		27-0863354
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7599 Anagram Dr., Eden Prairie, MN 55344

(Address of principal executive offices and zip code)

952-426-1383

(Registrant’s telephone number including area code)

(Registrant’s former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		NMTC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 of this Current Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated August 14, 2025
104		Cover Page Interactive Data File (embedded with Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUROONE MEDICAL TECHNOLOGIES CORPORATION
Dated: August 14, 2025
	By:	/s/ David Rosa
		David Rosa
		Chief Executive Officer

2